IntelliCell BioSciences Stem Cells Used to Successfully Treat Bell’s Palsy and Type I Diabetes Patient

NEW YORK, NY--(Marketwired - October 09, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels, announced today that it has supplied its cellular product, stromal vascular fraction cells (“SVFC”), to Regen Medical PC for the successful treatment of a Type I diabetic patient, who had developed bilateral permanent Bell’s palsy.

Previous medical history stated neither the patient’s diabetes nor Bell’s palsy had improved following 6 months of multiple congenital treatments. Following the unsuccessful treatments, the patient was remitted to the care of Dr. Steven Victor of ReGen Medical PC. Under the care of Dr. Victor, the patient received two treatments of ReGen Medical’s proprietary stem cell applications spaced 6 months apart. The result was a total resolution of the Bell’s palsy. The patient also noted that his insulin requirements for his Type I diabetes was reduced from 60 Units of Insulin daily to 5-10 Units of Insulin daily.

Dr. Steven Victor, Chairman and CEO of IntelliCell Biosciences, commented, “This was a clinical treatment utilizing IntelliCell’s SVFC method, which addressed an unmet clinical need. If not for our successful treatments, this patient was going to have to undergo corrective surgery of his eye and face and retire from his job due to slurred speech. Prior to our treatment the patient had been treated at some of most respected Medical Centers without getting any positive results. It is rewarding to have been part of a treatment for a patient where our cellular product helped change his quality of life. IntelliCell firmly believes that the future of medicine will entail utilizing cellular therapy for previously unmet clinical needs. Additionally, we were excited to see the patient’s insulin requirements reduced and we are looking into the possibility of our cellular product for future treatments of Diabetes Type I and Type II.”

Bell’s palsy is a form of facial paralysis resulting from a dysfunction of the cranial nerve VII (the facial nerve) causing an inability to control facial muscles on the affected side. Major complications of the condition are chronic loss of taste (ageusia), chronic facial spasms, facial pain and corneal infections.

Diabetes is a group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. Type I Diabetes results from the body’s failure to produce insulin, and currently requires the person to inject insulin or wear an insulin pump. All forms of diabetes increase the risk of long-term complications. The major long-term complications relate to damage to blood vessels. Diabetes also doubles the risk of cardiovascular disease.

“IntelliCell believes that we possess a paradigm shifting discovery that will change the manner in which patients are treated,” Dr. Victor continued. “We are confident that our relationships with the FDA and other governing bodies will allow us to rapidly expand the amounts of patients that we can treat using our SFV therapy.”

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “will reach,” “will change,” “will soon,” “should,” “could,” “would,” “may,” “can” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.